Search | Clinical Trials Finder

Conditions: Severe Eosinophilic Asthma, Nasal Polyps
Interventions: FASENRA(benralizumab); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more

Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions: Dexpramipexole Dihydrochloride, Placebo; Drug
Lead sponsor: Areteia Therapeutics; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 89
States / cities: Bakersfield, California • La Palma, California • Newport Beach, California + 73 more

Conditions: Hypereosinophilic Syndrome
Interventions: Depemokimab, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 8 more

Conditions: Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions: Mepolizumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 11
States / cities: Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more

Conditions: Asthma
Interventions: Mepolizumab 100mg, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Long Beach, California • Riverside, California • Denver, Colorado + 10 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more

Conditions: Hypereosinophilic Syndrome
Interventions: SCH55700; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypereosinophilic Syndrome
Interventions: mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 10
States / cities: San Diego, California • Denver, Colorado • Bethesda, Maryland + 7 more

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more

Conditions: Asthma
Interventions: Mepolizumab, Placebo, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more

Conditions: BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
Interventions: Ruxolitinib; Drug
Lead sponsor: William Shomali; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 4
States / cities: Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more

Conditions: Eosinophilic Asthma
Interventions: Dexpramipexole Dihydrochloride; Drug
Lead sponsor: Areteia Therapeutics; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic
Interventions: Dasatinib (BMS-354825); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Eosinophilic Asthma
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 27
States / cities: Lancaster, California • Long Beach, California • Northridge, California + 22 more

Conditions: Eosinophilic Asthma, Asthma
Interventions: Dexpramipexole, Placebo; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 36
States / cities: Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more

Conditions: Hypereosinophilic Syndrome
Interventions: dupilumab; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 26
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more

Conditions: Eosinophilic Asthma
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: Eosinophilic Asthma
Interventions: Observational; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypereosinophilic Syndrome
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more

Conditions: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 24
States / cities: Duarte, California • Stanford, California • Aurora, Colorado + 20 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 48
States / cities: Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more

Search by objective public record fields.

RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Phase III Long-Term Extension Study With Dexpramipexole

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma